4 hours DiaMedica Therapeutics (NASDAQ:DMAC) Research Coverage Started at HC Wainwright MarketBeat
HC Wainwright began coverage on shares of DiaMedica Therapeutics in a research note on Monday. They issued a “buy” rating and a $7.00 target price for the company.